AUSTIN, Texas, July 27, 2020 /PRNewswire/ — Iodine Software today unveiled its AwareCDI™ Suite for hospitals and health system finance and health information management leaders, powered by its proprietary Cognitive Emulation™ approach. The new software suite is designed to address clinical documentation integrity (CDI) and coding issues throughout the mid-revenue cycle in order to capture earned reimbursement and drive increased quality.
Today, mid-revenue cycle management encompasses multiple steps across clinical documentation, coding, charge capture, pre-bill reviews, and other claims preparation processes. However, ensuring the entirety of the patient encounter is accurately and compliantly reflected in the final code set submitted for reimbursement requires clinical judgment derived from years of experience in the field. Today, incorrect or incomplete coding leads to revenue leakage of up to $11.3 million annually per 250-bed hospital.1
To solve these challenges, Iodine has pioneered a new approach called Cognitive Emulation which uses proprietary AI technology and machine learning algorithms to think the way a clinician thinks and emulates clinical judgment. Iodine’s Cognitive Emulation approach powers the AwareCDI Suite, which delivers true clinical documentation reliability and a significant reduction in condition and revenue leakage across the entire mid-revenue cycle. To date, the Iodine Concurrent™ module within the AwareCDI Suite has helped nearly 500 hospitals recognize $1.5 billion in additional appropriate reimbursement annually.2
“Since its founding, Iodine Software has focused on reimagining the way hospitals and health systems can tap into the power of artificial intelligence and machine learning to transform finance operations, accelerate financial return, and improve quality. Given the complexities of the mid-revenue cycle, it’s clear that a new approach was needed to drive better results,” said William Chan, CEO and co-founder, Iodine Software. “With our new AwareCDI Suite, we are uniquely positioned to help hospitals and health systems go beyond cost containment and build revenue-accretive strategies for short- and long-term financial resiliency.”
A new way to think about the mid-revenue cycle
The AwareCDI Suite emulates the judgment of clinicians throughout the mid-revenue cycle to reliably identify areas of potential reimbursement opportunity while accelerating financial return, productivity, data accuracy, and quality metrics. It includes:
About Iodine Software
Iodine Software is a healthcare AI company that has pioneered a new machine learning approach — Cognitive Emulation™ — to help healthcare finance leaders build resilient organizations. Founded in 2010, Iodine’s technology unifies clinical concepts, evidence-based medicine, and deep machine learning to power revenue cycle solutions that maximize capture and data accuracy. To date, the Iodine AwareCDI™ Suite has helped nearly 500 hospitals recognize $1.5 billion in additional appropriate reimbursement annually. To learn more, visit iodinesoftware.com.
Contact: Adrienne Chen for Iodine Software, achen@iodinesoftware.com
(1) The Advisory Board, 2016
(2) Figures are based on a $6,000 modeled base rate and actual measured MCC capture performance from the 2019 Iodine Performance Cohort Analysis of 339 facilities that compared measured MCC capture and CMI impact for the Iodine usage period 9/1/2018-8/31/2019 against pre-Iodine baseline performance.
Related Images
iodine-software.png
Iodine Software
Iodine Software is a healthcare AI company that has pioneered a new machine learning approach — Cognitive Emulation — to help healthcare finance leaders build resilient organizations.
View original content to download multimedia:http://www.prnewswire.com/news-releases/iodine-software-unveils-awarecdi-software-suite-to-solve-mid-revenue-cycle-leakage-and-drive-financial-resiliency-for-health-systems-301100376.html
SOURCE Iodine Software
SINGAPORE, June 23, 2024 /PRNewswire/ -- Singapore-headquartered Juniper Biologics Pte Ltd (Juniper), a leading healthcare…
FRONTIER2 data presented at ISTH 2024 showed that up to 95% of people, who had…
Pemvidutide elicited significant weight loss and decreases in pro-inflammatory serum lipids associated with atherogenesis and…
TAIPEI, June 22, 2024 /PRNewswire/ -- The prestigious 2024 Tang Prize Laureates have been announced,…
Afrezza® Afrezza® (insulin human) Inhalation Powder. Study proves inhaled insulin is as effective as usual…
PURCHASE, NY, June 21, 2024 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader…